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BACKGROUND
Psoriatic arthritis (PsA) is a chronic inflammatory
disorder characterized by arthritis and psoriasis
variably associated with other extra-articular man-
ifestations (1-5). 
PsA is usually grouped among the seronegative
spondyloarthropathies (SpA), a class of diseases
encompassing ankylosing spondylitis (AS) and re-
active arthritis, with which it shares a number of
common immunogenetical, radiological, and clin-
ical features (1-5). 
PsA has traditionally been considered a milder and
less disabling disease compared with rheumatoid
arthritis (RA). However, this view has recently
been challenged by a number of studies showing
that approximately 40% of PsA patients develop
joint erosions and damage (6, 7). In addition, in cir-
ca 20-40% of patients, PsA can also affect the ax-
ial skeleton (so-called “psoriatic spondylitis”) (8),
leading to functional limitation and deformity akin
to, although usually less severe than that observed
in AS (9).
Due to the heterogenous clinical picture, with a pos-
sible combination in any individual patient of axial
disease, peripheral arthritis, enthesitis and dactylitis,
PsA is difficult to assess and validated assessment
tools are lacking. Recently, the Group for Research
and Assessments in Psoriasis and Psoriatic Arthri-
tis (GRAPPA) has contributed to the development
and validation of standardized tools to assess PsA.
We will review the existing assessment modalities
of PsA focusing on axial diasese, peripheral arthri-
tis, enthesitis and dactylitis. Measures of function
and disability recommended for PsA will be also
reviewed.
PERIPHERAL JOINT DISEASE
Peripheral joint disease activity
Assessments of peripheral joint disease activity in
PsA include the American College of Rheumatol-
ogy (ACR) joint count, the Ritchie index and the
28-joint count (10-12).
The ACR joint count documents the number of
joints with joint-line tenderness, stress pain, and/or
swelling. The total joint count (total number of ten-
der and/or swollen joints) may be calculated, or
separately the sum of the number of tender joints
or swollen joints. The ACR joint count is valid in
RA both in terms of its reproducibility and in terms
of its sensitivity to change with time. The ACR
joint count is a reliable measure of disease activi-
ty also in PsA, however it has not been tested
specifically for sensitivity to change over time.
The Ritchie index assesses the individual joints
according to the ACR joint count. It includes the
degree of tenderness and swelling of each joint on
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a 0-3 scale, but it does not include the distal inter-
phalangeal (DIP) joints of the feet. The Ritchie in-
dex demonstrated more observer-related variation
than did the ACR joint count in RA.
The 28-joint count is a reduced joint count which
includes both shoulders, elbows and wrists, all
metacarpalphalangeal joints, all proximal inter-
phalangeal joints of the hands, and both knees. It
has been studied in RA, but it has not been vali-
dated in PsA. The 28-joint count could not be ap-
propriate for PsA:
1) more than 50% of the patients have inflamma-
tion of the DIP joints;
2) in some patients arthritic manifestations are re-
stricted to DIP joints;
3) foot involvement is common in PsA.
Measures used to assess peripheral joint disease
in recent clinical trials in PsA
Psoriatic Arthritis Response Criteria (PsARC),
ACR response criteria (20, 50 e 70%) and EULAR
response criteria based on Disease Activity Score
(DAS) were used to assess joint disease in recent
clinical trials in PsA (13-18). These response mea-
sures include: assessment of tender and swollen
joints and patient - and physician - derived scores.
They successfully distinguished drug-treated from
placebo-treated patients.
Psoriatic Arthritis Response Criteria were de-
veloped by Clegg et al for the study of sulfasalazine
in PsA (13). They include:
- Physician global assessment (0-5 point scale)
(response: reduction by 1 score).
- Patient global assessment (0-5 point scale) (re-
sponse: reduction by 1 score).
- Tender joint count (76 or 68) (response: reduc-
tion of >30%).
- Swollen joint count: (76 or 68) (response: re-
duction of >30%).
Overall response is defined by improvement in 2
of 4 items, one of which must be a joint count;
there must not be worsening in any of the 4 items.
In recent PsA clinical trials where PsARC where
used as primary or secondary outcome measures,
they demonstrated differences between the drug -
and placebo-treated patients (Table I) (13-18).
Therefore these criteria are a valid outcome mea-
sure in PsA.
ACR response criteria (20, 50 e 70%) have been
extensively used in RA clinical trials. They include:
20% (50% or 70%) reduction in the tender joint
count
20% (50% or 70%) reduction in the swollen joint
count
+
a 20% (50 or 70%) reduction in 
3 of the following 5 additional measures:
patient and physician global assessments (VAS)
patient pain score (VAS)
disability (HAQ)
acute phase reactant (ESR or CRP)
Table I - Application of the PsARC as an outcome measures in recent PsA clinical trials.
Study drug (duration) Trial (No. of patients) PsARC, % responders 
drug group placebo group
Sulfasalazine (36 weeks) Clegg et al. (220) 55 45
Etanercept (12 weeks) Mease et al. (60) 87 23
Infliximab (16 weeks) Antoni et al. (100) 76,5 18
Etanercept (24 weeks) Mease et al. (205) 70 24
Leflunomide (24 weeks) Kaltwasser et al (188) 57,9 29,7
Adalimumab (24 weeks) Mease et al. (313) 60 23
Table II - Application of the ACR 20% improvement response criteria as an outcome measures in recent PsA clinical trials.
Study drug (duration) Trial (No. of patients) ACR20, % responders 
drug group placebo group
Etanercept (12 weeks) Mease et al. (60) 73 13
Infliximab (16 weeks) Antoni et al. (100) 69 8
Etanercept (24 weeks) Mease et al. (205) 50 13
Adalimumab (24 weeks) Mease et al. (313) 57 15
Leflunomide (24 weeks) Kalrwasser et al. (188) 38.5 20
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In PsA clinical trials the total number of joints
counted was increased to 78 for tenderness and 76
for swelling, including the 66 or 68 joints routine-
ly evaluated in an ACR joint count plus 10 addi-
tional joints often involved in PsA (the first car-
pometcarpal and the DIP joints of the toes). 
These criteria were included as outcome measures
(primary or secondary) in recent PsA clinical tri-
als and the differences observed in the responses
between drug- and placebo-treated patients indi-
cate that ACR response criteria for RA have valid-
ity in PsA trials (Table II) (14-18). 
EULAR response criteria are based on the Dis-
ease Activity Score (DAS):
- Ritchie Articular Index
- Swollen Joint Count
- ESR (mm/hour)
- Patients general health or global disease activ-
ity (VAS).
The EULAR response criteria include not only
change in disease activity, but also current disease
activity. To be classified as responders (good or
moderate), patients should have a significant
change in DAS and also low current disease activ-
ity. The DAS 28 includes only 28 joints.
A comparable validity for the EULAR and ACR re-
sponse criteria was demonstrated in RA.
In evaluating PsA disease activity EULAR re-
sponse criteria have the major limitation of ex-
cluding distal interphalangeal joints. 
The DAS and DAS 28 were evaluated as secondary
outcomes in the Infliximab Multinational Psoriat-
ic Arthritis Controlled Trial ( IMPACT) and they
distinguished infliximab from placebo-treated pa-
tients at 16 weeks (15).
In conclusion, based on their ability to distinguish
between drug-treated and placebo-treated patients,
the ACR, PsARC, and EULAR response criteria
for outcome assessment in RA appear to be valid
in the assessment of peripheral arthritis in PsA.
SPINAL DISEASE 
Spondylitis occurs in ~ 40% of patients with PsA,
but it is less severe than that of AS. Therefore, it is
possible that measures of axial disease originally
developed for AS may not be sufficiently sensitive
to change or accurate for use in PsA. The assessment
of spinal disease has not been included in clinical
PsA trials to date, as there are no acceptable tools. 
The most widely used measure of the inflammatory
activity of AS is the Bath Ankylosing Spondylitis
Disease Activity Index (BASDAI) which evaluates:
• VAS overall level of fatigue/tiredness past week
• VAS overall level of AS neck, back, or hip pain
past week.
• VAS overall level of pain/swelling in joints
other than neck, back or hips past week.
• VAS overall discomfort from any areas tender
to touch or pressure past week.
• VAS overall level of morning stiffness from
time of awakening past week.
• Duration and intensity (VAS) of morning
stiffness from time of awakening (up to 120
minutes).
BASDAI is simple, patient-completed, sensitive to
change over 3-weeks, and has been validated in
AS. Assessments in Ankylosing Spondylitis
(ASAS) Working Group have recommended that
significant clinical benefit in SA treatment is indi-
cated by reduction of BASDAI by 50% or a fall of
2 units (19). However there are some limitations in
using BASDAI as an outcome measure for PsA. 
BASDAI did not distinguish between patients with
PsA with a spondylarthropathy and those without
(20). BASDAI performs similarly for axial and pe-
ripheral PsA, but does not correlate well with ex-
ternal indicators of disease activity, such as treat-
ment decisions (21). In conclusion, waiting for fur-
ther studies of validation in PsA, BASDAI do no
function well and it is ambiguous as a measure of
disease activity in patients with PsA.
ASAS response criteria are a clinically valid,
easy-to-use measure of short term improvement in
AS validated in clinical trials (19). ASAS 20 or
40% response criteria could be used to measure
axial PsA disease activity and to assess therapeu-
tic response, but they must be validated in this con-
dition. ASAS 20 improvement criteria include: im-
provement of ≥20% and ≥10 units in at least 3 of
the following 4 domains: patient global assessment,
pain, function, inflammation + no worsening of
≥20% and ≥10 units in the remaining domain.
DACTYLITIS
Dactylitis occurs in 16-48% of cases of PsA (22).
Acute dactylitis has been shown to be a clinical in-
dicator of disease severity. However, chronic, non-
tender diffuse dactylitic swelling may be less clini-
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cally significant. An instrument suitable for quanti-
fying psoriatic dactylitis must be able to measure the
amount of swelling and distinguish tender from non-
tender digits. At the moment, there are no validat-
ed, sensitive measure for dactylitis. In our practice
we use a 0-2 scale (0 = none, 1 = present but mini-
mal, 2 = present and maximal) and we count all 20
digits where dactylitis is present (the joints in that
digit are not scored separately). Recently, a new
method for quantifying dactylitis based on digital
circumference and tenderness has been described
with a good inter and intraobserver reliability (23).
Measures used to assess dactylitis in recent clin-
ical trials in PsA
A simple scoring of present or absent dactylitis
was used in the IMPACT trial with infliximab (15),
in which statistically significant improvement of
dactylitis was demonstrated in the infliximab
group. Dactylitis was evaluated using a 0-3 scale,
based on the clinician’s judgement of relative sever-
ity, for each digit of the hand and toes in the trial
with adalimumab (18). In this trial dactylitis im-
proved, but the changes did not achieve statistical
significance comparing adalimumab treatment
group to placebo group.
ENTHESITIS
Two enthesitis measures have been developed for
spondyloarthropathies: the Mander index and the
Maastricht Ankylosing Spondylitis Enthesis Score
(MASES) (24, 25). The Mander index, which in-
cludes 66 sites, has been considered cumbersome
because of the large number of sites assessed. The
MASES index, which includes 13 anatomic sites is
more simple, has been validates in patients with
AS, but it has not yet been assessed in PsA trials.
Measures used to assess enthesitis in recent clin-
ical trials in PsA
Enthesitis was defined as present or absent on the
plantar fascia and insertion of the Achilles tendons
bilaterally. Enthesitis was significantly improved
with infliximab treatment but not with adalimum-
ab treatment compared to placebo (15, 18).
MEASURES OF FUNCTION AND DISABILITY
The following measures of function and disability
were validated in PsA: the Health Assessment
Questionnaire (HAQ) which assesses function re-
lated to arthritis and the Medical Outcomes Study
Short-Form 36 (SF-36) which is a generic quality
of life instrument (11).
A new quality of life measure (PsAQol) has been
recently developed for PsA but it requires valida-
tion (26).
The Health Assessment Questionnaire was de-
veloped by Fries et al for the assessment of dis-
ability in patients with RA (27). HAQ focuses on
physical disability (8 scales) and pain. A modifi-
cation of the HAQ for spondyloarthropaties (HAQ-
S) was also developed, which includes 2 spinal do-
mains. A further modification, HAQ for psoriasis
(HAQ-SK) was also studied in PsA patients.
Both HAQ and HAQ-S were tested in PsA patients,
both correlated with disease activity, and their
scores were almost identical. HAQ has been used
in several PsA therapy trials (11). 
SF-36 is a generic health assessment questionnaire,
which has been studied in a number of chronic dis-
eases including rheumatic conditions. SF-36 as-
sesses 8 domains: physical functioning, pain, vi-
tality, social functioning, psychological function-
ing, general health perceptions, and role limitations
due to physical and emotional problems. SF-36 has
been validated in PsA. In PsA SF-36 was equally
or more responsive than HAQ to short term
changes in perceived health status and inflamma-
tory disease activity. SF-36 has been used in sev-
eral PsA therapy trials (11).
Measures used to assess function and disability in
recent clinical trials in PsA 
Recently randomized controlled trials with anti-
TNF agents and leflunomide demonstrated sig-
nificant reductions in HAQ scores in the patient
group treated with the active drug compared to
placebo group. SF-36 has also demonstrated sig-
nificant improvement in recent PsA therapeutic
trials (15-18). 
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